Peter Stephen Keen

Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom.

Exosect Ltd. develops and provides pest management solutions. It enables pesticide manufacturers to improve the delivery of their formulations to overcome pest resistance, regulatory control and residues within the food chain. The firm offers Entostat delivery platform an electro statically charged micro powder that is formulated to microencapsulate synthetic active ingredients and Entomag delivery platform, a ferrous micro powder that enables the particle to be held in place to a suitable magnetic device and used to the targeted delivery of synthetic chemistry particularly for the control of crawling insects in the public health sector. It serves the agriculture, public health and animal health sectors. The company was founded by Philip Harris on April 29, 1999 and is headquartered in Winchester, the United Kingdom.

Serentis Ltd. discovered, developed and distributed pharmaceutical products. The company was founded by Tim Sharpington, Alan Rothaul, and Andy Baxter in 2006 and was headquartered in London, the United Kingdom.

Oval Medical Technologies Ltd. manufactures drug delivery devices focusing on vials, prefilled syringes, and autoinjectors. It provides an environment for the storage of all drugs including fragile biologics. The company was founded by Matthew Young in 2009 and is headquartered in Cambridge, the United Kingdom.

Horizon Discovery Ltd. develops and supplying patient-relevant drug discovery and diagnostic research tools. The frm also supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. The company was founded by Christopher John Torrance and Alberto Bardelli on February 14, 2005 and is headquartered in Cambridge, the United Kingdom.

Kiadis Pharma BV operates as a is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products include: ATIR101 and ATIR201. The firm’s products are based on hematopoietic blood-forming stem cell transplants from donors. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands.

Vectura Group Ltd. engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom.

Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom.

HealthCare Royalty Trust PLC is a closed-ended investment fund which intended to establish one or more wholly-owned subsidiaries for efficient portfolio management. The company was founded on December 15, 2015 and is headquartered in London, the United Kingdom.

Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom.

SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT.

Endomagnetics Ltd. develops surgical instruments used in the treatment of cancer. It offers SentiMag, a surgical instrument for use in the treatment of breast cancer and melanoma by helping surgeons to identify the sentinel lymph node for excision and subsequent histology to determine whether cancer has spread from a nearby tumor site. The company was founded by Quentin Pankhurst, Simon Hattersley, and Audrius Brazdeikis in April 2007 and is headquartered in Cambridge, the United Kingdom.